Apothecary NAD+ Injection Recalled for Lack of Sterility Assurance
Apothecary Pharma is recalling NAD+ Injection vials due to a lack of assurance of sterility. The product was distributed nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II due to a lack of assurance of sterility in an injectable product. The source does not report any illnesses, injuries, or deaths.
Plain-English summary
Apothecary Pharma LLC is recalling Apothecary NAD+ Injection 200 mg/mL, 6 mL Sterile Multi-Dose Vials. The recall is being conducted because of a lack of assurance of sterility in the product.
The affected product is identified by Lot # AP-202647 with a beyond-use date of 13-Oct-2026. The product is prescription-only and was distributed nationwide within the United States.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- Apothecary NAD+ Injection 200 mg/mL, 6 mL Sterile Multi-Dose Vial, Rx Only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC, 27513, NDC 85091-011-06.
- Manufacturer
- Apothecary Pharma LLC
- Category
- Drug — Injectable
- Hazard
- Affected units
- 1
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AP-202647
- BUD 13-Oct-2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Apothecary Pharma LLC
See all →- SevereApothecary Pharma Recalls Tirzepatide Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Artificial Tears Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereCarolina Infusion Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Ultra Lubricating Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereApothecary Pharma Recalls Tirzepatide Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- HighNAD+ Injectable Vials Recalled for Sterility Assurance Deficiency
FDA (Drugs) · 2023-08-30
- HighNAD+ Injectable Vials Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2022-07-20
- SevereAdvanced Physician Solutions Recalls Nanpyridoxine Injectable Due to Sterility Concerns
FDA (Drugs) · 2015-06-03
- HighInjectable NADH Recalled for Sterility Concerns at Manufacturing Facility
FDA (Drugs) · 2023-02-01
- HighFDA recalls NAD+ pharmaceutical powder vials due to sterility concerns
FDA (Drugs) · 2022-06-01